GSK to acquire US biotech group behind food allergy drug
Digest more
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...
RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.
The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...
InvestorsHub on MSN
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal
Shares in RAPT Therapeutics Inc (NASDAQ:RAPT) soared 63.6% on Tuesday after pharmaceutical major GSK plc (LSE:GSK) said it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback